Strongyloidiasis

Summary

Strongyloidiasis (MONDO:0005974) is a disease and 14 clinical trials. Top therapeutic interventions include ivermectin, albendazole, and diethylcarbamazine. A subtype of Rhabditida infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Clinical trials: 14

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000	0.06	Spain	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	strongyloidiasis
Mondo ID	MONDO:0005974
EFO	EFO:0007501
MeSH	D013322
Orphanet	76
DOID	DOID:10955
ICD-10-CM	B78
ICD-11	2088326190
NCIT	C128398
SNOMED CT	187176005
UMLS	C0038463
MedGen	20976
GARD	0008195
MedDRA	10042254
Is cancer (heuristic)	no

Also known as: Anguilluliasis · Anguillulosis

Disease family

This is a subtype of Rhabditida infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › Nematoda infectious disease › Rhabditida infectious disease › strongyloidiasis

Related subtypes (11): thelaziasis, ancylostomiasis, Ascaridida infectious disease, enterobiasis, mansonelliasis, oesophagostomiasis, setariasis, trichostrongylosis, dirofilariasis, dracunculiasis, onchocerciasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Ivermectin	Approved (phase 4)
Albendazole	Phase 3 (in late-stage trials)
Moxidectin	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 14.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE3	6
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07159373	PHASE3	NOT_YET_RECRUITING	Better Options for Lymphatic Filariasis Treatment
NCT00765024	PHASE3	COMPLETED	Ivermectin Versus Albendazole for Chronic Strongyloidiasis
NCT01570504	PHASE3	COMPLETED	Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis
NCT03605758	PHASE3	TERMINATED	Treatment of Strongyloides Infection
NCT03676140	PHASE3	COMPLETED	Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
NCT04844905	PHASE3	UNKNOWN	Adjunctive Ivermectin Mass Drug Administration for Malaria Control
NCT06373835	PHASE2	COMPLETED	Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis
NCT00001245	Not specified	COMPLETED	Study of Patients With Strongyloides Stercoralis Infection
NCT00207753	Not specified	COMPLETED	Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections
NCT02105714	Not specified	COMPLETED	Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
NCT04709848	Not specified	UNKNOWN	Strongyloides Stercoralis in Bone Marrow Transplant Recipients in the UK
NCT04999774	Not specified	COMPLETED	Evaluation of Strongyloidiasis in Ecuador: a fieLd Laboratory Accuracy Study
NCT05868005	Not specified	COMPLETED	Delivering a Multi-disease Screening Tool to Migrant Populations
NCT07296198	Not specified	COMPLETED	Strongyloidiasis at CHRU Nancy: Evaluation of the Performance of Serological Tests and Disease-associated Characteristics

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IVERMECTIN	4	4
ALBENDAZOLE	4	2
DIETHYLCARBAMAZINE	4	1
EMODEPSIDE	2	1
CHEMBL263291	0	4
CHEMBL4082099	0	4
CHEMBL4788951	0	4
CHEMBL48977	0	1